You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

CLINICAL TRIALS PROFILE FOR VATALANIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Vatalanib

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00056446 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer	Completed	Bayer	Phase 3	The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.
NCT00056446 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer	Completed	Novartis Pharmaceuticals	Phase 3	The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.
NCT00056459 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.	Completed	Bayer	Phase 3	To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
NCT00056459 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.	Completed	Novartis	Phase 3	To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
NCT00072475 ↗	Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes	Completed	National Cancer Institute (NCI)	Phase 2	RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.
NCT00072475 ↗	Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes	Completed	Alliance for Clinical Trials in Oncology	Phase 2	RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Vatalanib

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Unspecified Adult Solid Tumor, Protocol Specific	4
Brain and Central Nervous System Tumors	3
Sarcoma	2
Metastatic Neuroendocrine Tumors	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Carcinoid Tumor	4
Neoplasms	4
Neuroendocrine Tumors	4
Nervous System Neoplasms	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Vatalanib

Trials by Country

Map
Table

Trials by Country for
Location	Trials
United States	116
Canada	9
Italy	3
Switzerland	3
United Kingdom	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for
Location	Trials
North Carolina	6
California	5
Minnesota	5
Illinois	5
Louisiana	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Vatalanib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	9
Phase 1/Phase 2	6
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	18
Unknown status	3
Terminated	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vatalanib

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
Novartis	8
National Cancer Institute (NCI)	7
Novartis Pharmaceuticals	5
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Other	28
Industry	17
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.